Your browser doesn't support javascript.
loading
Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li, Jun; Yue, Huiran; Yu, Hailin; Lu, Xin; Xue, Xiaohong.
  • Li J; Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, No.419, Fangxie Road, Shanghai, 200011, China.
  • Yue H; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, 200011, China.
  • Yu H; Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, No.419, Fangxie Road, Shanghai, 200011, China.
  • Lu X; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, 200011, China.
  • Xue X; Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, No.419, Fangxie Road, Shanghai, 200011, China.
BMC Cancer ; 21(1): 67, 2021 Jan 14.
Article en En | MEDLINE | ID: mdl-33446144

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Biomarcadores de Tumor / Regulación Enzimológica de la Expresión Génica / Regulación Neoplásica de la Expresión Génica / Nicotinamida N-Metiltransferasa / Neoplasias de las Trompas Uterinas / Bevacizumab Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Biomarcadores de Tumor / Regulación Enzimológica de la Expresión Génica / Regulación Neoplásica de la Expresión Génica / Nicotinamida N-Metiltransferasa / Neoplasias de las Trompas Uterinas / Bevacizumab Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2021 Tipo del documento: Article